Crescendo Bioscience, a wholly-owned subsidiary of Myriad Genetics, Inc. , today announced that six studies on Vectra® DA will be featured at the American College of Rheumatology (ACR) meeting being held Nov. 3-8, 2017 in San Diego,
SALT LAKE CITY, Oct. 30, 2017 –Crescendo Bioscience, a wholly-owned subsidiary of Myriad Genetics, Inc. (NASDAQ: MYGN), today announced that six studies on Vectra® DA will be featured at the American College of Rheumatology (ACR) meeting being held Nov. 3-8, 2017 in San Diego, Calif. Vectra DA has been shown to be the best predictor of the risk of radiographic progression, and the data from six studies had demonstrated that a high Vectra DA score was associated with a high risk of radiographic progression.
"Our presentations at this year’s ACR reinforce our commitment to improving care for people living with rheumatoid arthritis," said Elena Hitraya, M.D., Ph.D., chief medical officer, Crescendo Bioscience. "The new data add to a robust body of scientific knowledge supporting Vectra DA, which has been shown in multiple studies to be the best predictor of the risk of joint damage in patients with RA."
Please visit Crescendo Biosciences at Booth #712 for information about Vectra DA. Abstracts are available online at: https://www.rheumatology.org/Annual-Meeting/Abstracts. Below is a list of the highlighted Crescendo Bioscience presentations at ACR (#ACR17):
Podium Presentations
- Title: Effect of age and body mass index (BMI) on multi-biomarker disease activity (MBDA) score in patients with rheumatoid arthritis.
Presenter: Kerri Ford.
Date: Monday, Nov. 6, 2017: 4:30-6:00 p.m. PT.
Abstract: 1900.
- Title: Validation of biomarkers to predict flare in polyarticular JIA upon stopping anti-TNF therapy.
Presenter: Daniel Lovell.
Date: Tuesday, Nov. 7, 2017: 4:30-6:00 p.m. PT.
Abstract: 2858.
Poster Presentations
- Title: Impact of the multi-biomarker disease activity score results on whether rheumatologists changed biologic therapy for RA patients.
Presenter: Jeffrey Curtis.
Date: Sunday, Nov. 5, 2017: 9:00-11:00 a.m. PT.
Abstract: 129.
- Title: High multi-biomarker disease activity score is associated with high risk of radiographic progression in six studies.
Presenter: Jeffrey Curtis.
Date: Sunday, Nov. 5, 2017: 9:00-11:00 a.m. PT.
Abstract: 438.
- Title: Prediction of Cardiovascular Events in Rheumatoid Arthritis Patients Using a Multi-Biomarker of Disease Activity
Presenter: Fenglong Xie.
Date: Sunday, Nov. 5, 2017: 9:00-11:00 a.m. PT.
Abstract: 138.
- Title: Development of an adjusted multi-biomarker disease activity score for rheumatoid arthritis that accounts for age, sex, and adiposity, with evaluation of ability to predict risk for radiographic damage.
Presenter: Jeffrey Curtis.
Date: Monday, Nov.6, 2017: 9:00-11:00 a.m. PT.
Abstract: 1371.
About Rheumatoid Arthritis
Rheumatoid arthritis is a chronic, systemic inflammatory condition that is often characterized by symptoms that include pain, stiffness and inflammation of the joints, and in some cases, joint destruction and disability. An estimated 1.5 million Americans have the condition, which affects nearly three times as many women as men. While the cause of RA is unknown, many cases are believed to result from genetic and environmental factors.
About Vectra® DA
Vectra DA is the only multi-biomarker blood test for rheumatoid arthritis disease activity that integrates the concentrations of 12 serum proteins associated with RA disease activity into a single objective score, on a scale of 1 to 100, to help physicians make more informed treatment decisions. Vectra DA testing is performed at the Crescendo Bioscience state-of-the-art CLIA (Clinical Laboratory Improvement Amendments) facility. Test results are reported to the physician 5 to 7 days from shipping of the specimen to Crescendo Bioscience. Physicians can receive test results via standard mail, by fax or via the private web portal, VectraView. For more information on Vectra DA, please visit: www.Vectra-DA.com.
About Crescendo Bioscience
Crescendo Bioscience, a wholly-owned subsidiary of Myriad Genetics, Inc., is a molecular diagnostics company dedicated to developing and commercializing quantitative blood tests for rheumatoid arthritis (RA) and other autoimmune diseases, located in South San Francisco, Calif. Crescendo Bioscience develops quantitative, objective, reproducible blood tests to provide rheumatologists with deeper clinical insight to help enable more effective management of patients with autoimmune and inflammatory diseases. For more information, please visit the company website at www.CrescendoBio.com.
About Myriad Genetics
Myriad Genetics Inc., is a leading personalized medicine company dedicated to being a trusted advisor transforming patient lives worldwide with pioneering molecular diagnostics. Myriad discovers and commercializes molecular diagnostic tests that: determine the risk of developing disease, accurately diagnose disease, assess the risk of disease progression, and guide treatment decisions across six major medical specialties where molecular diagnostics can significantly improve patient care and lower healthcare costs. Myriad is focused on three strategic imperatives: maintaining leadership in an expanding hereditary cancer market, diversifying its product portfolio through the introduction of new products and increasing the revenue contribution from international markets. For more information on how Myriad is making a difference, please visit the Company's website: www.myriad.com.
Myriad, the Myriad logo, BART, BRACAnalysis, Colaris, Colaris AP, EndoPredict, myPath, myRisk, Myriad myRisk, myRisk Hereditary Cancer, myChoice, myPlan, BRACAnalysis CDx, Tumor BRACAnalysis CDx, myChoice HRD, Vectra DA, GeneSight, EndoPredict and Prolaris are trademarks or registered trademarks of Myriad Genetics, Inc. or its wholly owned subsidiaries in the United States and foreign countries. MYGN-F, MYGN-G
